BioPlus Acquisition Corp. Logo

BioPlus Acquisition Corp.

BIOS

(1.8)
Stock Price

10,80 USD

8.55% ROA

5.99% ROE

3.63x PER

Market Cap.

209.072.163,00 USD

4.31% DER

0% Yield

0% NPM

BioPlus Acquisition Corp. Stock Analysis

BioPlus Acquisition Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioPlus Acquisition Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.35x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (4%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

ROE in an average range (5.99%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (8.55%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

BioPlus Acquisition Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioPlus Acquisition Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioPlus Acquisition Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioPlus Acquisition Corp. Revenue
Year Revenue Growth
1993 100.000
1994 109.300.000 99.91%
1995 213.900.000 48.9%
1996 283.200.000 24.47%
1997 242.300.000 -16.88%
1998 451.100.000 46.29%
1999 377.400.000 -19.53%
2000 369.800.000 -2.06%
2001 456.600.000 19.01%
2002 576.600.000 20.81%
2003 588.800.000 2.07%
2004 630.500.000 6.61%
2005 1.073.200.000 41.25%
2006 1.152.500.000 6.88%
2007 1.197.700.000 3.77%
2008 1.401.900.000 14.57%
2009 1.329.500.000 -5.45%
2010 1.638.600.000 18.86%
2011 0 0%
2012 662.600.000 100%
2013 842.200.000 21.33%
2014 984.100.000 14.42%
2015 982.200.000 -0.19%
2016 935.600.000 -4.98%
2017 817.200.000 -14.49%
2018 708.900.000 -15.28%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioPlus Acquisition Corp. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioPlus Acquisition Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 100.000
1994 5.300.000 98.11%
1995 8.000.000 33.75%
1996 11.600.000 31.03%
1997 19.100.000 39.27%
1998 23.100.000 17.32%
1999 28.000.000 17.5%
2000 33.900.000 17.4%
2001 38.500.000 11.95%
2002 45.900.000 16.12%
2003 50.600.000 9.29%
2004 52.800.000 4.17%
2005 109.300.000 51.69%
2006 129.200.000 15.4%
2007 125.300.000 -3.11%
2008 129.100.000 2.94%
2009 140.600.000 8.18%
2010 226.300.000 37.87%
2011 0 0%
2012 198.500.000 100%
2013 254.000.000 21.85%
2014 319.400.000 20.48%
2015 83.600.000 -282.06%
2016 66.000.000 -26.67%
2017 63.300.000 -4.27%
2018 47.300.000 -33.83%
2021 0 0%
2022 0 0%
2023 5.115.964 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioPlus Acquisition Corp. EBITDA
Year EBITDA Growth
1993 0
1994 -2.210.000 100%
1995 -5.730.000 61.43%
1996 -29.620.000 80.65%
1997 -10.110.000 -192.98%
1998 7.690.000 231.47%
1999 420.000 -1730.95%
2000 3.980.000 89.45%
2001 21.360.000 81.37%
2002 28.660.000 25.47%
2003 19.480.000 -47.13%
2004 15.730.000 -23.84%
2005 -19.980.000 178.73%
2006 -11.440.000 -74.65%
2007 9.390.000 221.83%
2008 -82.500.000 111.38%
2009 16.630.000 596.09%
2010 -36.670.000 145.35%
2011 39.386.000 193.1%
2012 86.367.000 54.4%
2013 -39.003.000 321.44%
2014 -174.600.000 77.66%
2015 -335.760.000 48%
2016 -56.150.000 -497.97%
2017 -24.970.000 -124.87%
2018 -84.900.000 70.59%
2021 0 0%
2022 -1.171.196 100%
2023 -5.115.964 77.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioPlus Acquisition Corp. Gross Profit
Year Gross Profit Growth
1993 100.000
1994 2.600.000 96.15%
1995 500.000 -420%
1996 5.100.000 90.2%
1997 3.300.000 -54.55%
1998 29.700.000 88.89%
1999 30.300.000 1.98%
2000 35.200.000 13.92%
2001 53.400.000 34.08%
2002 70.600.000 24.36%
2003 68.600.000 -2.92%
2004 68.100.000 -0.73%
2005 116.200.000 41.39%
2006 119.600.000 2.84%
2007 137.000.000 12.7%
2008 142.200.000 3.66%
2009 157.800.000 9.89%
2010 260.400.000 39.4%
2011 0 0%
2012 224.900.000 100%
2013 271.800.000 17.26%
2014 261.100.000 -4.1%
2015 260.900.000 -0.08%
2016 265.600.000 1.77%
2017 269.300.000 1.37%
2018 243.000.000 -10.82%
2021 0 0%
2022 -1.171.196 100%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioPlus Acquisition Corp. Net Profit
Year Net Profit Growth
1993 0
1994 -2.700.000 100%
1995 -7.500.000 64%
1996 -33.200.000 77.41%
1997 -15.800.000 -110.13%
1998 2.600.000 707.69%
1999 -4.800.000 154.17%
2000 -1.800.000 -166.67%
2001 14.200.000 112.68%
2002 18.700.000 24.06%
2003 9.100.000 -105.49%
2004 7.000.000 -30%
2005 -23.900.000 129.29%
2006 -38.300.000 37.6%
2007 3.300.000 1260.61%
2008 -74.000.000 104.46%
2009 54.100.000 236.78%
2010 -69.100.000 178.29%
2011 -33.106.000 -108.72%
2012 -8.400.000 -294.12%
2013 -53.600.000 84.33%
2014 -143.400.000 62.62%
2015 -303.500.000 52.75%
2016 -34.400.000 -782.27%
2017 -131.000.000 73.74%
2018 -51.600.000 -153.88%
2021 0 0%
2022 5.163.060 100%
2023 4.962.192 -4.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioPlus Acquisition Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 -1 0%
1995 -2 100%
1996 -3 66.67%
1997 -1 -200%
1998 0 0%
1999 0 0%
2000 0 0%
2001 1 0%
2002 1 0%
2003 0 0%
2004 0 0%
2005 -1 0%
2006 -1 100%
2007 0 0%
2008 -2 100%
2009 1 200%
2010 -1 200%
2011 -1 0%
2012 0 0%
2013 -1 0%
2014 -2 100%
2015 -4 50%
2016 0 0%
2017 -1 100%
2018 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioPlus Acquisition Corp. Free Cashflow
Year Free Cashflow Growth
1994 4.680.000
1995 600.000 -680%
1996 -8.510.000 107.05%
1997 -4.660.000 -82.62%
1998 -18.550.000 74.88%
1999 10.720.000 273.04%
2000 4.700.000 -128.09%
2001 8.300.000 43.37%
2002 18.700.000 55.61%
2003 13.380.000 -39.76%
2004 2.230.000 -500%
2005 -11.550.000 119.31%
2006 -35.300.000 67.28%
2007 18.660.000 289.17%
2008 -16.210.000 215.11%
2009 17.010.000 195.3%
2010 -32.530.000 152.29%
2011 26.507.000 222.72%
2012 -16.166.000 263.97%
2013 -337.548.000 95.21%
2014 -45.250.000 -645.96%
2015 -76.280.000 40.68%
2016 -52.410.000 -45.54%
2017 -9.440.000 -455.19%
2018 -33.980.000 72.22%
2022 -691.465 -4814.2%
2023 -878.919 21.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioPlus Acquisition Corp. Operating Cashflow
Year Operating Cashflow Growth
1994 5.490.000
1995 1.400.000 -292.14%
1996 -7.640.000 118.32%
1997 -3.080.000 -148.05%
1998 -16.380.000 81.2%
1999 12.900.000 226.98%
2000 11.330.000 -13.86%
2001 10.930.000 -3.66%
2002 20.800.000 47.45%
2003 14.340.000 -45.05%
2004 3.290.000 -335.87%
2005 -6.420.000 151.25%
2006 -29.860.000 78.5%
2007 24.190.000 223.44%
2008 -8.750.000 376.46%
2009 22.750.000 138.46%
2010 -21.420.000 206.21%
2011 26.970.000 179.42%
2012 26.880.000 -0.33%
2013 -54.550.000 149.28%
2014 -31.420.000 -73.62%
2015 -64.740.000 51.47%
2016 -42.770.000 -51.37%
2017 -760.000 -5527.63%
2018 -20.100.000 96.22%
2022 -691.465 -2806.87%
2023 -878.919 21.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioPlus Acquisition Corp. Capital Expenditure
Year Capital Expenditure Growth
1994 810.000
1995 800.000 -1.25%
1996 870.000 8.05%
1997 1.580.000 44.94%
1998 2.170.000 27.19%
1999 2.180.000 0.46%
2000 6.630.000 67.12%
2001 2.630.000 -152.09%
2002 2.100.000 -25.24%
2003 960.000 -118.75%
2004 1.060.000 9.43%
2005 5.130.000 79.34%
2006 5.440.000 5.7%
2007 5.530.000 1.63%
2008 7.460.000 25.87%
2009 5.740.000 -29.97%
2010 11.110.000 48.33%
2011 463.000 -2299.57%
2012 43.046.000 98.92%
2013 282.998.000 84.79%
2014 13.830.000 -1946.26%
2015 11.540.000 -19.84%
2016 9.640.000 -19.71%
2017 8.680.000 -11.06%
2018 13.880.000 37.46%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioPlus Acquisition Corp. Equity
Year Equity Growth
1994 -3.700.000
1995 -11.500.000 67.83%
1996 30.100.000 138.21%
1997 16.800.000 -79.17%
1998 39.100.000 57.03%
1999 35.200.000 -11.08%
2000 39.500.000 10.89%
2001 60.300.000 34.49%
2002 94.200.000 35.99%
2003 107.200.000 12.13%
2004 115.700.000 7.35%
2005 195.800.000 40.91%
2006 161.800.000 -21.01%
2007 166.200.000 2.65%
2008 95.500.000 -74.03%
2009 155.800.000 38.7%
2010 200.100.000 22.14%
2011 215.300.000 7.06%
2012 293.400.000 26.62%
2013 354.600.000 17.26%
2014 216.800.000 -63.56%
2015 -18.000.000 1304.44%
2016 40.400.000 144.55%
2017 -2.700.000 1596.3%
2018 -50.700.000 94.67%
2021 221.001.779 122.94%
2022 222.997.711 0.9%
2023 121.850.828 -83.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioPlus Acquisition Corp. Assets
Year Assets Growth
1994 15.300.000
1995 18.900.000 19.05%
1996 61.800.000 69.42%
1997 62.700.000 1.44%
1998 110.100.000 43.05%
1999 115.700.000 4.84%
2000 116.400.000 0.6%
2001 139.800.000 16.74%
2002 182.200.000 23.27%
2003 171.200.000 -6.43%
2004 186.500.000 8.2%
2005 288.600.000 35.38%
2006 305.500.000 5.53%
2007 296.800.000 -2.93%
2008 247.000.000 -20.16%
2009 287.200.000 14%
2010 664.000.000 56.75%
2011 677.100.000 1.93%
2012 642.400.000 -5.4%
2013 936.900.000 31.43%
2014 824.700.000 -13.6%
2015 546.500.000 -50.91%
2016 607.700.000 10.07%
2017 603.100.000 -0.76%
2018 583.900.000 -3.29%
2021 235.980.915 -147.44%
2022 238.324.586 0.98%
2023 138.630.045 -71.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioPlus Acquisition Corp. Liabilities
Year Liabilities Growth
1994 19.000.000
1995 30.400.000 37.5%
1996 31.700.000 4.1%
1997 45.900.000 30.94%
1998 71.100.000 35.44%
1999 80.500.000 11.68%
2000 76.900.000 -4.68%
2001 79.500.000 3.27%
2002 88.000.000 9.66%
2003 64.000.000 -37.5%
2004 70.800.000 9.6%
2005 92.800.000 23.71%
2006 143.600.000 35.38%
2007 130.600.000 -9.95%
2008 151.400.000 13.74%
2009 131.400.000 -15.22%
2010 463.900.000 71.67%
2011 461.800.000 -0.45%
2012 349.000.000 -32.32%
2013 582.300.000 40.07%
2014 607.900.000 4.21%
2015 564.500.000 -7.69%
2016 567.300.000 0.49%
2017 605.800.000 6.36%
2018 634.700.000 4.55%
2021 14.979.136 -4137.23%
2022 15.326.875 2.27%
2023 16.779.217 8.66%

BioPlus Acquisition Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
2.98
Price to Earning Ratio
3.63x
Price To Sales Ratio
0x
POCF Ratio
-26.65
PFCF Ratio
-129.65
Price to Book Ratio
0.35
EV to Sales
0
EV Over EBITDA
-99.09
EV to Operating CashFlow
-132.9
EV to FreeCashFlow
-132.9
Earnings Yield
0.28
FreeCashFlow Yield
-0.01
Market Cap
0,21 Bil.
Enterprise Value
0,21 Bil.
Graham Number
45.28
Graham NetNet
30.56

Income Statement Metrics

Net Income per Share
2.98
Income Quality
-0.28
ROE
0.06
Return On Assets
0.09
Return On Capital Employed
-0.02
Net Income per EBT
2.04
EBT Per Ebit
-2.68
Ebit per Revenue
0
Effective Tax Rate
-1.04

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.41
Free CashFlow per Share
-0.41
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.03
Return on Tangible Assets
0.09
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
34,78
Book Value per Share
30,61
Tangible Book Value per Share
30.61
Shareholders Equity per Share
30.61
Interest Debt per Share
-0.2
Debt to Equity
0.04
Debt to Assets
0.04
Net Debt to EBITDA
-2.43
Current Ratio
0.1
Tangible Asset Value
0,12 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
0.04
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioPlus Acquisition Corp. Dividends
Year Dividends Growth

BioPlus Acquisition Corp. Profile

About BioPlus Acquisition Corp.

BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.

CEO
Mr. R. Ross Haghighat
Employee
0
Address
260 Madison Avenue
New York, 10026

BioPlus Acquisition Corp. Executives & BODs

BioPlus Acquisition Corp. Executives & BODs
# Name Age
1 Mr. Ross Haghighat
Chief Executive Officer, Chief Financial Officer & Director
70
2 Mr. Jonathan M. N. Rigby MBA
Chairman & Chief Bus. Officer
70
3 Mr. R. Ross Haghighat
Chief Executive Officer, Chief Financial Officer & Director
70

BioPlus Acquisition Corp. Competitors